Biotech companies at PepTalk 2027

Jan 18–21, 2027 Carlsbad, CA ~1k attendees Website

33 biotech companies are at PepTalk 2027 — 46 presentations on the program. Most represented: Generate Biomedicines (2 on the program), Zymeworks (2 on the program), Kite Pharma (2 on the program). 11 of them have their own page in this guide. As of Oct 17, 2026.

All 166 organizations at PepTalk 2027 →

Showing 1–15 of 33 organizations

Organization	PepTalk 2027 Attendance
Generate Biomedicines Somerville, MA
generatebiomedicines.com Biotech Designs antibodies and other protein drugs with generative machine-learning models and its own lab, and has candidates in clinical trials.	Chair Tue Jan 19 8:35am–8:40am Chairperson’s Opening Remarks Analytical Intelligence Panel Tue Jan 19 4:55pm–5:25pm AI's Real Impact on Biologic Drug Discovery: The Honest Scorecard Plenary · with Novo Nordisk, Prescient Design, Eli Lilly Predictive and AI-driven protein science Talk Wed Jan 20 11:40am–12:10pm Advancing Developability: From Lead Generation to Developable-by-Design Analytical Intelligence
Zymeworks
zymeworks.com Biotech Clinical-stage biotech developing multispecific antibodies, antibody-drug conjugates and engineered cytokines; created the Azymetric bispecific platform.	Panel Tue Jan 19 11:50am–12:20pm Selecting the Optimal Multispecific Format: Engineering Strategies from Discovery to Development Multispecifics Engineering & Design · with Rondo Therapeutics, AstraZeneca, Xencor +2 more Chair Wed Jan 20 2:25pm–2:30pm Chairperson's Opening Remarks Emerging T Cell Engagers Talk Thu Jan 21 3:10pm–3:40pm Engineering IL-7 to Enhance Anti-Tumor Activity and Cytokine Delivery to the Tumor Microenvironment Emerging T Cell Engagers
Kite Pharma Santa Monica, CA
kitepharma.com Biotech Gilead-owned cell therapy company making and selling CAR T-cell treatments for blood cancers.	Talk Mon Jan 18 4:00pm–4:30pm Bridging the Gap between Experimental Protein Data and AI-Guided Insights in the Context of CAR T SYMPOSIUM: Predictive Protein Production Talk Wed Jan 20 9:05am–9:35am Engineering Complex Lentiviral Payloads: Platform Development for Protein Expression Testing in Multicistronic Cell Therapy Constructs Recombinant Protein Production - Part 1
92Bio Hayward, CA
92biotech.com Biotech Clinical-stage company developing multispecific T cell engagers for cancer, including a FOLR1-targeted candidate for ovarian cancer and a CD123 engager for AML.	Talk Wed Jan 20 2:30pm–3:00pm NTB921: A Differentiated CD123 x Pan Delta T Cell Engager Setting a New Bar for Activity and Safety in R/R AML Emerging T Cell Engagers Chair Thu Jan 21 8:35am–8:40am Chairperson's Remarks Emerging T Cell Engagers
Aizen Therapeutics San Diego, CA
aizentx.com Biotech Uses generative AI to design peptide drugs built from mirror-image and other non-natural amino acids, aiming at oral medicines for immune disorders.	Talk Mon Jan 18 10:00am–10:30am Beyond Nature: De novo Design of Non-Canonical Peptide Drugs SYMPOSIUM: Peptide Drug Hunting—From Emerging Technologies to Clinical Impact Talk Thu Jan 21 2:05pm–2:30pm Beyond Nature: Advancing de novo Non-Canonical Peptides toward the Clinic Peptide Therapeutics: Emerging Modalities & Development
BigHat Biosciences San Mateo, CA
bighatbio.com Biotech Designs antibody therapeutics by pairing machine learning with a high-throughput wet lab, for its own pipeline and pharma partners.	Talk Thu Jan 21 9:10am–9:40am Engineering CEACAM6 × CD3 T Cell Engagers: AND-, OR-, and NOT-Gate Strategies for Precision Immunotherapy Emerging T Cell Engagers Chair Thu Jan 21 1:35pm–1:40pm Chairperson's Remarks Emerging T Cell Engagers
BioMarin San Rafael, CA
biomarin.com Biotech Develops and markets enzyme replacement and other therapies for rare genetic diseases.	Talk Thu Jan 21 2:00pm–2:20pm Accelerating Recombinant Protein Production: Reusable Workflows and Decision Frameworks across Therapeutic Modalities Recombinant Protein Production - Part 2 / Tools for Purification and Quality Panel Thu Jan 21 3:00pm–3:40pm Building Effective Cross-Functional Protein Production Teams Recombinant Protein Production - Part 2 / Tools for Purification and Quality · with Thomson Instrument Company, UCLA, AstraZeneca +1 more
ProFound Therapeutics
profoundtx.com Biotech Flagship Pioneering company mapping previously unannotated proteins in the human proteome to find new protein therapeutics and drug targets.	Panel Wed Jan 20 4:35pm–4:55pm Women in Science Meet-Up Plenary Chair Thu Jan 21 8:35am–8:40am Chairperson's Remarks Peptide Therapeutics: Emerging Modalities & Development
Rondo Therapeutics Hayward, CA
rondotx.com Biotech Clinical-stage biotech developing bispecific antibodies that engage T cells and costimulatory receptors against solid tumors.	Panel Tue Jan 19 11:50am–12:20pm Selecting the Optimal Multispecific Format: Engineering Strategies from Discovery to Development Multispecifics Engineering & Design · with AstraZeneca, Xencor, Eli Lilly +2 more Talk Thu Jan 21 2:10pm–2:40pm Engagement of Costimulatory Receptors as an Emerging Frontier in Solid-Tumor Treatments Emerging T Cell Engagers
Septerna South San Francisco, CA
septerna.com Biotech Biotech discovering oral small molecule drugs for G protein-coupled receptors, using a platform that produces the receptors in native-like functional states.	Talk Tue Jan 19 9:40am–10:10am Chimerization of Orthologous Protein Sequences to Solve Protein Expression and Production Challenges Recombinant Protein Production - Part 1 Panel Tue Jan 19 1:30pm–2:00pm Building Better Data for Predictive Protein Expression Recombinant Protein Production - Part 1 · with University College London, University of Surrey, Cell-Free Group +1 more
Vilya Seattle, WA
vilya.ai Biotech Uses AI models and computational design to create macrocycle drug candidates aimed at targets usually reached only by injected biologics.	Chair Mon Jan 18 1:30pm–1:35pm Chairperson's Remarks SYMPOSIUM: Peptide Drug Hunting—From Emerging Technologies to Clinical Impact Panel Mon Jan 18 4:30pm–5:00pm Breaking Down Silos—Integrating Disciplines to Accelerate Peptide Drug Discovery SYMPOSIUM: Peptide Drug Hunting—From Emerging Technologies to Clinical Impact · with EPOC Scientific, University of Florida, University of Queensland +1 more
Aureka Biotechnologies
aurekabio.com Biotech Start-up using an in-house AI and digital biology platform to discover antibody drugs for cardiometabolic and inflammatory diseases.	Talk Tue Jan 19 9:40am–10:10am Closing the Loop: AI-Driven Discovery of Functional Multispecific Antibodies through High-Throughput Single-Cell Screening Multispecifics Engineering & Design
Biomunex Pharmaceuticals Paris, France
biomunex.com Biotech French biotech building bispecific and multispecific antibodies on its BiXAb platform, including engagers that direct MAIT cells against solid tumors.	Talk Wed Jan 20 3:00pm–3:30pm MAIT Engagers: Potent and Safe Immune Cell Engagers for the Treatment of Cancer Emerging T Cell Engagers
Constructive Bio Cambridge, UK
constructive.bio Biotech Rewrites the genetic code to make proteins and peptides containing non-canonical amino acids, for its own pipeline and for partners.	Talk Thu Jan 21 8:40am–9:10am New-to-Nature Therapeutics with an Expanded Genetic Code Peptide Therapeutics: Emerging Modalities & Development
Denali Therapeutics South San Francisco, CA
denalitherapeutics.com Biotech Develops medicines for neurodegenerative and lysosomal storage diseases, engineering enzymes and antibodies to cross the blood-brain barrier.	Talk Mon Jan 18 4:30pm–5:00pm Utilizing Functional Yeast Display for Engineering Lysosomal Enzymes Suitable as ERTs SYMPOSIUM: Display of Biologics